Travel? Shopping, Movie Trailer? Music video? Scams Exposed? News? Horoscopes? Investment. Search. We have an international audience so publish in different languages
The pen is mightier than the sword - A picture is worth a thousand words
Shares
of Zillow traded higher in Tuesday's session after the online
real-estate database announced it had reached a settlement with rival
Move. The settlement deal averts a trial which would've taken place
later this month. Move and the National Association of Realtors were
seeking up to $2 billion in damages over allegations that Zillow
executives brought trade secrets with them when they left Move in 2014.
Zillow settled the suit for just $130 million dollars. On word of the
settlement, Barclays upgraded Zillow's shares to EQUAL WEIGHT from
UNDERWEIGHT. The firm also raised the stock's price target to $32 from
$20. This year, Zillow shares are up 37 percent.
BATM
Advanced Communications (LON:BVC) chief executive Zvi Marom tells
Proactive Investors that the company turned a corner in 2015 and has
enough finance to continue to do everything in their programme in the
year ahead.
“The contract we just signed took three years of
testing to convince that we have is the best of breed. Obviously we will
have more contracts in the coming years – this is very obvious” he
says.
Marom says BATM is billing in markets they have not seen
before is trying to bundle cyber together with networking in European
markets in particular. “ All the units we are supplying are cyber-ready –
I don’t see any other suppliers doing this” he says.
• While it may not be backed by robust volume (conviction), risk appetite inches higher with an 11-month SPX high
• Pound volatility remains extreme as EUR/GBP swings lower and GBP/USD temporarily surges intraday
• The RBA bolstered the Australian Dollar, what will the RBNZ decision do to the New Zealand currency?
Dilma
Rousseff, the former leftist guerrilla who became the first woman
president of Latin America's largest country, is now fighting for her
political survival.
Brazil's immensely popular former president
Luiz Inacio Lula da Silva, chose his chief of staff to carry on with his
legacy of economic growth with social justice.
But it didn't last. By the time Rousseff began her second term in 2015, Brazil was in turmoil.
Now
Rousseff has been suspended to face an impeachment trial - abandoned by
her allies and millions of Brazilians who accuse her of driving the
nation's once healthy economy into the ground and of turning a blind eye
to corruption within her own left-wing party.
It's the material
political soap operas are made of: almost daily corruption scandals are
splattering every political party, most recently, that of interim
President Michel Temer.
This week, more leaked phone
conversations revealed that two of his top ministers, including the man
in charge of combatting corruption, were apparently trying to derail
ongoing investigations into a multi-billion dollar bribery scheme.
Temer, who was until last month the vice president, turned against Dilma Rousseff, so she could face impeachment.
Rousseff is charged with having tampered with fiscal accounts to hide a massive budget deficit in order to get re-elected.
Yet, unlike a great many of those seeking her impeachment, she is not being accused of stealing money for herself.
In
fact at least 60 percent of Brazilian lawmakers are under investigation
or indictment for crimes ranging from attempted murder to massive
corruption, including the president of the senate who will be overseeing
the impeachment trial.
Rousseff claims her enemies are punishing
her for refusing to block corruption investigations, but will the
latest scandals involving the interim government be enough to save her?
Al
Jazeera's Lucia Newman speaks to President Dilma Rouseff in Brasilia as
the suspended leader faces a controversial impeachment trial which
could remove her permanently from the presidency.
Rouseff
discusses why she'll fight to be reinstated, the political fragmentation
in the country, and what she plans to do to earn back the trust of the
Brazilian people if she wins the Senate vote.
More from Talk To Al Jazeera on:
Gervais
Williams, fund manager at Miton Group PLC (LON:MGR) says for fund
managers it is all about “growing that dividend” as “good and growing
income is really what’s driving the market at the moment”.
He says
the diverse income fund, which returned 4% last year to investors, is
“very open minded” as long as there is dividend growth.
The fund buys
both FTSE100 companies, such as Legal & General Group plc
(LON:LGEN), but also AIM stocks, which Williams says are “particularly
under discovered”.
Around 15% is invested in FTSE100 companies,
slightly higher than last year due to BREXIT uncertainties, but 65%
remains in “small-micro” where Williams sees “the best opportunities”.
Stocks
head into the trading day at the highest levels this year. Indexes
rallied to 2016 highs as Federal Reserve Chair Janet Yellen said
interest rate hikes were needed but hedged on the timing of those.
Verizon plans to submit a second-round bid of around $3 billion for
Yahoo core internet business, which was much less than the $8 billion or
so that was expected. The Wall Street Journal says a private equity
firm, TPG Capital, is also expected to make an offer. There could be
another round of bidding before a decision is made. Valeant reported its
delayed first quarter results. Results missed the mark and will cut its
full year earnings and revenue guidance. The new CEO said the company
is making progress in stabilizing its business, which has been through
controversy over price increases, questions about accounting and
concerns over the use of a mail-order pharmacy.
Valeant
Pharmaceuticals is set to release results before the bell Tuesday.
Analysts are anticipating the Botox maker to report adjusted earnings of
$1.36 a share, that's down $1 from a year ago. Revenue estimates for
this quarter are expected to grow about 8.7% to about $2.4 billion.
Tuesday is Valeant's second quarterly report since its pricing and
compliance scandals were revealed. The Fill or Kill team will be keeping
a close eye on whether or not Valeant will beat top and bottom line
estimates.. and if there is any further information on how the drug
maker plans to reduce its debt.
